GlassScriptPhysician profile
Yadana Kyaw
NPI 1134393473
$3,702.75
in general payments reported to CMS, 2019-2025
25 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $509 · 2021: $267 · 2022: $357 · 2023: $627 · 2024: $475 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.36 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $749.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $693.51 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $383.44 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $366.97 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $314.91 | 2019-2025 | Tezspire, Airsupra, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.94 | 2019-2025 | Ofev |
| Genzyme Corporation | $197.11 | 2022-2025 | |
| Harmony Biosciences LLC | $103.31 | 2022-2024 | Wakix |
| Grifols USA, LLC | $77.22 | 2019-2021 | |
| Electromed, INC. | $70.31 | 2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $60.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $56.29 | 2023-2024 | Winrevair |
| Mylan Specialty L.P. | $50.50 | 2022-2023 | Yupelri |
| Amgen INC. | $42.42 | 2023-2024 | Tezspire |
| United Therapeutics Corporation | $40.18 | 2021-2023 | Tyvaso |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.01 | 2021-2024 | |
| La Jolla Pharmaceutical Company | $31.36 | 2019-2022 | |
| Advanced Respiratory, INC | $26.12 | 2020-2021 | |
| Gilead Sciences, INC. | $20.97 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.43 | 2022 | |
| Zoll Respicardia, INC. | $20.09 | 2023 | Remede System |
| Fisher & Paykel Healthcare INC | $17.99 | 2024 | Fisher & Paykel Healthcare |
| Pfizer INC. | $17.10 | 2024 | |
| Ambu INC. | $15.29 | 2022 | |
| Baxter Healthcare | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yadana Kyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.